Impact Analysis of Statin Discontinuation on Healthcare Resource Utilization (HCRU) and Cost of Care in Patients With Atherosclerotic Cardiovascular Disease (ASCVD) in the US
Author(s)
Vishan Khatavkar, MBA1, Aditi Paul, MBA1, Ina Kukreja, MBA, PT1, Rishav Singla, MBA1, Abhimanyu Roy, MBA1, Abhinav Nayyar, MBBS, MBA1, Arunima Sachdev, MA1, Vikash Kumar Verma, MBA, PharmD1, Louis Brooks Jr, MA2, Rahul Goyal, BS Tech3, Marissa Seligman, BS Pharma4.
1Optum, Gurgaon, India, 2Optum, Bloomsbury, NJ, USA, 3Optum, Phoenix, AZ, USA, 4Optum, Boston, MA, USA.
1Optum, Gurgaon, India, 2Optum, Bloomsbury, NJ, USA, 3Optum, Phoenix, AZ, USA, 4Optum, Boston, MA, USA.
Presentation Documents
OBJECTIVES: Statins are prescribed as first line of therapy in ASCVD patients; however, most of the patients do not achieve the critical benefit because of treatment discontinuation within a year. The objective is to evaluate the impact of statin discontinuation on the HCRU and costs.
METHODS: Optum Research Databases was used, and the patient identification period was from January 2017 to December 2018. It included ASCVD patients who began statin therapy within 30 days of an ASCVD event and maintained continuous eligibility for 12 months before and after the index date (earliest claim of statin therapy). Patients with an ASCVD event or statin prescription during the baseline period were excluded. The patients were monitored for 12 months from the start of statin therapy to assess treatment discontinuation. Those who maintained statin therapy for 12 months without a gap exceeding 30 days were classified as the continuous group, while those who discontinued statin therapy (for reasons other than death) were classified as the discontinuous group. The study compared HCRU and cost of care between these two groups.
RESULTS: Among 21,004 ASCVD patients who started statin therapy within 30 days of the ASCVD event, the average age was 67.2 years, 8,608 (40.9%) were female, and 7,425 (35%) were commercially insured. During the follow-up period, 5,361 (25.5%) patients discontinued statin therapy. Compared to the continuous group, the discontinuous group had significantly higher emergency room visits (2.0 vs 1.7, p<0.001) and length of hospital stay (4.4 vs 3.8, p=0.006), whereas no. of inpatient hospitalizations was similar. In terms of medical cost, per patient per month (PPPM) emergency costs were significantly higher for the discontinuous group compared to the continuous group ($112.7 vs $97.7, p<0.001).
CONCLUSIONS: The study results indicate higher HCRU and costs among ASCVD patients who discontinued statin therapy, highlighting the need for strategies to improve adherence.
METHODS: Optum Research Databases was used, and the patient identification period was from January 2017 to December 2018. It included ASCVD patients who began statin therapy within 30 days of an ASCVD event and maintained continuous eligibility for 12 months before and after the index date (earliest claim of statin therapy). Patients with an ASCVD event or statin prescription during the baseline period were excluded. The patients were monitored for 12 months from the start of statin therapy to assess treatment discontinuation. Those who maintained statin therapy for 12 months without a gap exceeding 30 days were classified as the continuous group, while those who discontinued statin therapy (for reasons other than death) were classified as the discontinuous group. The study compared HCRU and cost of care between these two groups.
RESULTS: Among 21,004 ASCVD patients who started statin therapy within 30 days of the ASCVD event, the average age was 67.2 years, 8,608 (40.9%) were female, and 7,425 (35%) were commercially insured. During the follow-up period, 5,361 (25.5%) patients discontinued statin therapy. Compared to the continuous group, the discontinuous group had significantly higher emergency room visits (2.0 vs 1.7, p<0.001) and length of hospital stay (4.4 vs 3.8, p=0.006), whereas no. of inpatient hospitalizations was similar. In terms of medical cost, per patient per month (PPPM) emergency costs were significantly higher for the discontinuous group compared to the continuous group ($112.7 vs $97.7, p<0.001).
CONCLUSIONS: The study results indicate higher HCRU and costs among ASCVD patients who discontinued statin therapy, highlighting the need for strategies to improve adherence.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE414
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)